☰

Maxim Markovic - Publications

Affiliations: 
Stanford University School of Medicine, Palo Alto, CA, United States 
Tree Info Similar researchers PubMed Report error

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Rovira-Clavé X, Drainas AP, Jiang S, Bai Y, Baron M, Zhu B, Dallas AE, Lee MC, Chu TP, Holzem A, Ayyagari R, Bhattacharya D, McCaffrey EF, Greenwald NF, Markovic M, et al. Spatial epitope barcoding reveals clonal tumor patch behaviors. Cancer Cell. PMID 36240778 DOI: 10.1016/j.ccell.2022.09.014  0.389
2020 Tal MC, Torrez Dulgeroff LB, Myers L, Cham LB, Mayer-Barber KD, Bohrer AC, Castro E, Yiu YY, Lopez Angel C, Pham E, Carmody AB, Messer RJ, Gars E, Kortmann J, Markovic M, et al. Upregulation of CD47 Is a Host Checkpoint Response to Pathogen Recognition. Mbio. 11. PMID 32576678 DOI: 10.1128/Mbio.01293-20  0.784
2019 Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. PMID 31367043 DOI: 10.1038/S41586-019-1456-0  0.72
2019 Myers LM, Tal MC, Torrez Dulgeroff LB, Carmody AB, Messer RJ, Gulati G, Yiu YY, Staron MM, Angel CL, Sinha R, Markovic M, Pham EA, Fram B, Ahmed A, Newman AM, et al. A functional subset of CD8 T cells during chronic exhaustion is defined by SIRPα expression. Nature Communications. 10: 794. PMID 30770827 DOI: 10.1038/S41467-019-08637-9  0.774
2018 Feng M, Marjon KD, Zhu F, Weissman-Tsukamoto R, Levett A, Sullivan K, Kao KS, Markovic M, Bump PA, Jackson HM, Choi TS, Chen J, Banuelos AM, Liu J, Gip P, et al. Programmed cell removal by calreticulin in tissue homeostasis and cancer. Nature Communications. 9: 3194. PMID 30097573 DOI: 10.1038/S41467-018-05211-7  0.664
2018 Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 19: 76-84. PMID 29180808 DOI: 10.1038/S41590-017-0004-Z  0.527
Show low-probability matches.